Lantern Pharma (LTRN) corporate presentation summary

Platform and technology

• RADRⓇ AI platform accelerates oncology drug discovery, reducing early-stage development timelines by 70% and costs by 80%.

• AI-driven insights and biomarkers increase clinical trial success odds by 12x and enable patient stratification with 88% accuracy.

• PredictBBBTM module achieves 94% accuracy in predicting blood-brain barrier permeability, supporting CNS drug development.

• Zeta, a multi-agent AI system, integrates vast biomedical data for rare cancer research, enabling rapid discovery and trial design.

• The platform leverages over 200 billion data points and advanced machine learning for drug discovery and development.

Pipeline and clinical programs

• Ten disclosed drug programs, including LP-300 for NSCLC in never smokers, LP-184 for DDR-deficient solid tumors, and LP-284 for B-cell NHL.

• LP-300 Phase 2 Harmonic™ trial shows 86% clinical benefit rate and durable responses in NSCLC never smokers.

• LP-184 completed Phase 1a with favorable safety and efficacy; Phase 1b/2 trials planned for TNBC, NSCLC, bladder cancer, and glioblastoma.

• LP-284 demonstrated complete metabolic response in a heavily pre-treated lymphoma patient and is being explored for SLE.

• STAR-001 (LP-184 for CNS cancers) shows >20% survival increase in mouse models and has received multiple FDA designations.

Clinical and preclinical results

• LP-300 nearly doubled survival outcomes for NSCLC never smokers in prior trials, with a 125% increase in median 2-year survival.

• LP-184 demonstrated complete regression in DDR-deficient PDX models and strong synergy with PARP inhibitors and anti-PD1 therapies.

• LP-284 showed superior preclinical responses in NHL models, including those resistant to standard-of-care agents.

• STAR-001 achieved 82–91% tumor growth inhibition in ATRT pediatric brain cancer models.